Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics, Inc. (Nasdaq: AKRO) is a clinical-stage biotechnology company based in South San Francisco, developing innovative treatments for major metabolic diseases, including non-alcoholic steatohepatitis (NASH). Focused on creating best-in-class medicines, Akero's lead clinical program centers on efruxifermin (EFX), a modified FGF21 protein designed to reduce liver fat, inflammation, and fibrosis. EFX is engineered to target both the liver and adipose tissue, offering potential comprehensive benefits to NASH patients.
Building on over two decades of FGF21 research, Akero has achieved significant milestones. Their Phase 2b HARMONY study, evaluating EFX in pre-cirrhotic NASH patients, demonstrated impressive results at Week 96, including substantial fibrosis improvement and liver health biomarkers. Additionally, the SYNCHRONY program encompasses multiple Phase 3 clinical trials aimed at both cirrhotic and pre-cirrhotic NASH patients, further validating the efficacy and safety profile of EFX.
Akero's rigorous clinical trials and outstanding engagement with the FDA underscore their commitment to addressing high unmet medical needs. Their recent public stock offering has bolstered financial stability, ensuring sustained progress in their groundbreaking research and development efforts. For more information, visit Akero Therapeutics and follow them on LinkedIn and Twitter.
Akero Therapeutics has announced significant findings from the Phase 2b HARMONY study on efruxifermin (EFX) presented at the EASL Congress 2024. The 96-week data demonstrated that EFX achieved a ≥1-stage improvement in fibrosis without worsening metabolic dysfunction-associated steatohepatitis (MASH) in patients. At 96 weeks, 75% of patients on 50 mg EFX and 46% on 28 mg EFX showed improvement, compared to 24% for placebo. Additionally, 36% and 31% of patients on 50 mg and 28 mg EFX, respectively, exhibited a 2-stage improvement in fibrosis. The treatment was well tolerated, with no liver injury or decompensation events. A poster presentation highlighted EFX's positive impact on extracellular matrix remodeling and liver injury biomarkers, suggesting enhanced metabolic and liver health.
Akero Therapeutics (Nasdaq: AKRO), a clinical-stage company developing treatments for serious metabolic diseases, announced it will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET in New York. The presentation will be available via live webcast on the company's investor relations webpage, with an archived replay accessible afterward.
Akero Therapeutics, Inc. (Nasdaq: AKRO) reported successful Week 96 results from the Phase 2b HARMONY study, showing significant improvements in fibrosis stage with the drug EFX in patients with pre-cirrhotic MASH. The company is well-funded with over $900 million in cash following an equity offering. Phase 3 SYNCHRONY studies are on track, including the SYNCHRONY Outcomes study for patients with cirrhosis. Akero also closed a public offering of common stock, raising approximately $366.9 million. Financially, the company has $903.7 million in cash and saw increased expenses related to clinical studies and operations.
Akero Therapeutics, a clinical-stage company focused on treatments for metabolic diseases, will present at the BofA Securities 2024 Health Care Conference on May 14, 2024, in Las Vegas, NV. The presentation can be accessed through the company's website.
Akero Therapeutics, Inc. appoints Scott Gangloff as Chief Technology Officer. Gangloff brings 30 years of experience in biopharmaceutical development and manufacturing, having led teams through BLAs and product approvals. He will contribute to the commercialization and manufacturing strategy of efruxifermin, a Phase 3 trial drug for MASH treatment.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
What is Akero Therapeutics' main focus?
What is efruxifermin (EFX)?
What are the key results from the HARMONY study?
What is the SYNCHRONY program?
How is Akero Therapeutics funded for their research?
What is the significance of Akero's work with the FDA?
Where is Akero Therapeutics headquartered?
How can I get more information about Akero Therapeutics?
